Leading MS center Vall d’Hebron, Barcelona to advance neuroradiological practice with icobrain AI portfolio

Leuven, Belgium and Chicago, IL, USA, August 9th 2018 - icometrix, the world leader in software solutions to obtain clinically meaningful data from brain MRI scans, is pleased to announce that their CE-marked and FDA-cleared icobrain portfolio will now be used as part of clinical routine in Vall d’Hebron, Barcelona, which is one of the most renowned European neurology centers. icobrain will be used to assist in the enhanced diagnosis and follow up of people with MS and dementia as it enables enables radiologists and neurologists to quantify and track different forms of brain abnormalities on patients’ MRI scans.

“Being able to detect important changes in my patients’ MRI scans using the advanced algorithms of icometrix allows our clinic to improve patient care, as we are now able to detect disease activity that very well could have been missed by the radiologist’s naked eye.” says Prof. Alex Rovira, Head of MRI and Neuroradiology at University Hospital Vall d'Hebron. “The world of radiology is clearly evolving towards quantification very rapidly, this is becoming standard of care now” adds Prof. Rovira.

“It is great to see the enthusiasm with which MRI quantification is becoming routine clinical practice around the world. Our icobrain portfolio which is used in patients with MS, dementia and traumatic brain injury, doesn’t replace the work of the radiologist, as their work is still essential in detecting large anomalies that algorithms simply aren’t able to, as well as providing the hugely important human element to hospital visits.” explains Wim Van Hecke, CEO of icometrix, “What we do provide is the quantification of exactly what is going on in the brain of these patients to an unprecedented level.”

Knowing what types of lesions or what patterns of atrophy patients have with a high degree of precision, and how this brain damage evolves over time, has a great clinical significance for physicians to make diagnostic and treatment decisions. Furthermore, getting an early and accurate diagnosis is valuable for patients with dementia, as this allows them and their family to plan for the future.